Cardiovascular and metabolic diseases are among the leading causes of death and disability in the developed world, and a growing concern in developing nations. Charles River offers a comprehensive cardiovascular and metabolic disease drug discovery service portfolio, including innovative target identification and validation platforms, complex in vitro and in vivo pharmacology models, and a strong chemistry and disease biology foundation, all of which assist in translating basic research to clinical reality.

We provide a number of in vivo pharmacology models for obesity, diabetes and its complications, fatty liver disease, atherosclerosis, vascular inflammation, dyslipidemia, and other metabolic and cardiovascular diseases. Combining our well-characterized in vivo models and broad suite of translational biomarkers, our partners the flexibility they need to demonstrate the therapeutic efficacy of their compounds.